NEW YORK (360Dx) – Fujirebio today announced a deal with Janssen Pharmaceutical to develop and commercialize a test for use with the drug maker's investigational oral BACE inhibitor, atabecestat, for Alzheimer's disease.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.